Place · Level 3 · Supplement
Glucosamine + Chondroitin
关节软骨的组成原料 · 但吃下去能不能补到膝盖是另一回事 · 大试验总体阴性, 中重度疼痛者可能受益 · 值得三个月试用再决定
Last updated
Story path
Chapter 1
Joint components
Joint components
Glucosamine + chondroitin = two basic components of the glycosaminoglycans (GAGs) in joint cartilage.
Chemistry:
Glucosamine: amino sugar, the core monomer of GAGsChondroitin sulfate: long GAG chain containing glucosamine units + sulfate groupsTogether they form proteoglycans + aggrecan → the cartilage matrix
Body sources:
Endogenous synthesis: from glucose + glutamineFood: animal cartilage (chicken feet / chicken cartilage / bone broth) — trace amountsSupplements: mainly from crustacean shells (sulfate / HCl) or bovine cartilage extracts
Why the atlas must cover this:
Global $5B+ market + top 10 supplement sales in ChinaClinical evidence is mixed — some RCTs positive, some negative2024 consensus (ACR / OARSI): not first-line, but some patients benefit; individualised decisionGAIT 2006 NEJM is the key RCT — the atlas must report it honestlyArthritis is highly prevalent globally (50% of Chinese 65+ show radiographic degeneration)
Two types of osteoarthritis (OA):
Primary OA: ageing + chronic wear, the main indication on this islandSecondary OA: trauma / rheumatoid / otherPain ≠ radiographic degeneration: people with severe imaging may have no pain; people with mild imaging can have severe pain — high inter-individual variability
Glucosamine forms:
Glucosamine sulfate: European prescription drug (originator Rotta, Dona); most RCTs use thisGlucosamine hydrochloride: dominant US OTC form; GAIT used thisN-acetylglucosamine (NAG): different, mainly gut use (ulcerative colitis)The two salts differ slightly in bioavailability; some research considers sulfate marginally superior (the sulfate group may itself be useful), inconsistent
Chemistry:
Glucosamine: amino sugar, the core monomer of GAGsChondroitin sulfate: long GAG chain containing glucosamine units + sulfate groupsTogether they form proteoglycans + aggrecan → the cartilage matrix
Body sources:
Endogenous synthesis: from glucose + glutamineFood: animal cartilage (chicken feet / chicken cartilage / bone broth) — trace amountsSupplements: mainly from crustacean shells (sulfate / HCl) or bovine cartilage extracts
Why the atlas must cover this:
Global $5B+ market + top 10 supplement sales in ChinaClinical evidence is mixed — some RCTs positive, some negative2024 consensus (ACR / OARSI): not first-line, but some patients benefit; individualised decisionGAIT 2006 NEJM is the key RCT — the atlas must report it honestlyArthritis is highly prevalent globally (50% of Chinese 65+ show radiographic degeneration)
Two types of osteoarthritis (OA):
Primary OA: ageing + chronic wear, the main indication on this islandSecondary OA: trauma / rheumatoid / otherPain ≠ radiographic degeneration: people with severe imaging may have no pain; people with mild imaging can have severe pain — high inter-individual variability
Glucosamine forms:
Glucosamine sulfate: European prescription drug (originator Rotta, Dona); most RCTs use thisGlucosamine hydrochloride: dominant US OTC form; GAIT used thisN-acetylglucosamine (NAG): different, mainly gut use (ulcerative colitis)The two salts differ slightly in bioavailability; some research considers sulfate marginally superior (the sulfate group may itself be useful), inconsistent
机制 · 吃下去的那一粒, 最后到了哪里
先把这一岛开头那个问题, 换成身体里的问法: 一粒葡萄糖胺从嘴里下去, 最后有多少能站到膝盖那块软骨上? 这条路上有三道关, 每一道都在打折。第一关 · 肠道和肝脏: 它被并进了全身的糖池
葡萄糖胺是一种氨基糖——说白了就是一个葡萄糖分子上挂了个氨基。小肠能把它吸收进血液, 但它进了血并不认路: 血流先经门静脉送进肝脏, 肝细胞把其中大部分就地拆掉当能量、或者改造成别的糖, 剩下的才继续往全身走。更要紧的是, 身体本来就在自己造它 (从葡萄糖加谷氨酰胺出发, 几乎每个细胞都会造); 食物里也藏着一点点, 主要在动物软骨里——鸡爪、鸡软骨、牛骨汤; 补剂则多半从虾蟹甲壳或牛软骨提取。所以你吞下去的那一份, 是往一个本来就在不停补货的池子里加水, 而不是一条通向膝盖的专线。
结果就是: 口服之后血里能测到的葡萄糖胺浓度, 比培养皿里做软骨细胞实验时用的浓度低了两三个数量级。那些葡萄糖胺能刺激软骨细胞多造基质的体外实验, 用的是身体里根本达不到的浓度。这一条单独就够解释, 为什么试管里漂亮、放到人身上却常常测不出差别。
第二关 · 软骨素是个大家伙, 整条进不去
软骨素不是小分子, 而是一条由几十个糖单元串起来、还挂满硫酸基的长链。肠壁吸收养分靠的是专认小分子的转运通道, 这么长的链条基本过不去; 它大部分在肠腔里就被消化酶和肠道细菌剪成短片段和单糖, 再以碎片的形式被吸收。也就是说, 你吃进去的软骨素, 到血里时多半已经不是软骨素了, 真正以完整长链进入循环的比例很低。
第三关 · 软骨没有血管, 血送到了也送不进去
这一关最容易被忽略, 却最关键。你身上几乎每一块组织都有毛细血管贴着送货, 唯独关节软骨没有——它是全身最厚的无血管组织之一。软骨细胞被埋在自己分泌的基质里, 拿养分只能靠扩散: 养分先溶进关节腔的滑液, 再一点一点渗进基质。
那滑液靠什么把养分压进去? 靠你动。走路、上下楼、屈伸膝盖的时候, 软骨被反复压扁又回弹, 像海绵一样把旧液挤出去、把新液吸回来。这就是为什么长期不动的关节反而退化得更快, 也是为什么这一岛后面把运动排在所有补剂前面——运动本身就是软骨唯一的送货泵。
三关连起来看
肠道剪掉一部分、肝脏截留一部分、剩下的分散进全身、最后还要靠关节活动一点一点渗进一块没有血管的组织。这条链上每一步都在稀释, 而没有任何一步是朝着膝盖的。所以软骨的原料这个说法本身没错, 错的是它后面被默认接上的那半句——所以吃了就能补到软骨。原料和成品之间隔着一整条运输线, 而这条线不归你吃的那粒药管。
这不等于它一定无效 (下一幕会看真人试验怎么说), 但它解释了一件事: 为什么这类补剂的效应, 从机制上就注定是小的。
临床 · 关节炎有两种, 而片子和疼痛常常对不上
这类补剂为什么值得认真拆关节炎在中老年人里很常见——中国 65 岁以上的人, 大约一半在 X 光片上能看到软骨退变; 加上葡萄糖胺加软骨素本身是个几十亿美元的大市场, 买的人极多。所以它值得一条一条看证据, 而不是一句没用或者神药打发掉。
先分清是哪一种关节炎
原发性骨关节炎 (OA): 衰老加上几十年的慢性磨损慢慢磨出来的, 这一岛讲的主要是它继发性 OA: 先有别的事——半月板撕裂、韧带断过、类风湿性关节炎、痛风——关节退变跟在后面。病因不同, 处理也不同, 别拿这一岛的结论直接往上套
一个反常识、但一定要记住的事实: 疼痛和片子上的退变并不一一对应。
片子很糟的人可能几乎不痛, 只有轻度退变的人可能痛得下不了楼, 个体差异非常大。这不是拍片技术的问题, 而是因为磨损和疼痛根本不是同一件事——下一幕会讲清楚, 疼到底是从哪个组织发出来的。
这个事实有两个很实际的后果:
判断一个办法有没有用, 不能只看影像。影像没变但人不疼了, 是真的好转; 影像好看但人很疼, 也是真的疼你自己试补剂时, 该记录的是疼不疼、能不能爬楼、能走多远, 而不是片子有没有变好——后者在几个月里根本看不出变化
买之前 · 三个长得很像的名字
药店货架上、以及这一岛后面要讲的试验里, 会反复出现三个长得很像的名字, 买之前先分清。葡萄糖胺硫酸盐 (Glucosamine sulfate): 欧洲把它当处方药管 (原研产品叫 Dona), 大部分做出阳性结果的试验用的是它。
葡萄糖胺盐酸盐 (Glucosamine hydrochloride): 美国药店的主流形态, 后面那个著名的阴性试验 GAIT 用的就是它。
这两种里的葡萄糖胺其实是同一个分子, 区别只在配对的离子: 一个配硫酸根, 一个配氯离子。进了胃里离子就分开, 真正被吸收的都是同一个葡萄糖胺; 吸收比例略有差异, 谁更好至今没定论。但用了哪一种盐和试验结果是阳性还是阴性这两件事高度重合, 所以它被反复拿出来讨论——下一幕的深度页专门算这笔账。
N-乙酰葡萄糖胺 (NAG): 名字只差几个字, 却是完全不同的东西——它在葡萄糖胺上多挂了一个乙酰基, 研究主要用在肠道黏膜方向, 不是关节补剂。看清标签, 别买错。
Chapter 2
GAIT · null but subgroup
GAIT · null but subgroup
GAIT (Glucosamine/chondroitin Arthritis Intervention Trial, Clegg et al 2006 NEJM) — the key RCT this atlas must cover:
Design:
N = 1,583 knee-OA patients5-arm randomisation × 24 weeks:Glucosamine HCl 500 mg × 3/dayChondroitin sulfate 400 mg × 3/dayCombination (glucosamine + chondroitin)Celecoxib 200 mg/day (NSAID, positive control)Placebo
Primary result:
Overall: no significant difference (except celecoxib was clearly superior)Glucosamine alone / chondroitin alone / combination did not differ from placebo
Subgroup analysis (post-hoc, interpret carefully):
Moderate-to-severe pain subgroup (high WOMAC pain): glucosamine + chondroitin combination vs placebo → +20% response rate (79% vs 54%)Mild pain: large placebo effect + no significant supplement effect
GAIT2 (Sawitzke 2010, 2-year continuation):
Clinical outcomes only — this paper measured no structure at allNo arm beat placebo on the primary endpoint (20% WOMAC pain reduction over 24 months): celecoxib 1.21, glucosamine 1.16, combination 0.83, chondroitin alone 0.69, none significantThe investigators went looking for the 2006 moderate-to-severe subgroup signal by testing interaction terms — none was statistically significant. It did not replicateStructure was tested separately (Sawitzke 2008): 24-month joint space width by X-ray, no significant difference. The moderate-to-severe pain subgroup, small magnitude
Other key RCTs + meta-analyses:
MOVES Trial (2016): combination vs celecoxib → non-inferior (but no placebo arm, interpretation caveat)Wandel 2010 BMJ meta-analysis: 10 RCTs, clinical efficacy negative overall (below the minimal clinically important difference)Bruyère 2019 ESCEO guideline: gives prescription-grade crystalline glucosamine sulfate a strong recommendation (GRADE). ESCEO issues only strong/weak — it has no letter grades, so the Level B once quoted here was never in that document2019 OARSI guideline: strongly recommends against every glucosamine and chondroitin formulation — pharmaceutical grade included, not just OTC. This is the strongest negative guideline in the field, and it is the one ESCEO disagrees with2019 ACR / Arthritis Foundation guideline: not recommended (weak evidence)
Why the conclusions are so contested:
GAIT used the HCl salt; some positive RCTs used the sulfate — are they the same?Production / quality variability is large: OTC label content ≠ actual contentSubgroup effects: moderate-to-severe pain may benefit, mild does notPlacebo effect is large: OA pain is subjective; placebo can reach 30-50% improvement
Atlas position:
Overall evidence weak-to-moderateWorth a 3-month trial to see personal response (especially moderate-to-severe pain)Don't expect "new joints"Does not replace weight loss + strength training + physiotherapy + NSAIDs + medical evaluation
Design:
N = 1,583 knee-OA patients5-arm randomisation × 24 weeks:Glucosamine HCl 500 mg × 3/dayChondroitin sulfate 400 mg × 3/dayCombination (glucosamine + chondroitin)Celecoxib 200 mg/day (NSAID, positive control)Placebo
Primary result:
Overall: no significant difference (except celecoxib was clearly superior)Glucosamine alone / chondroitin alone / combination did not differ from placebo
Subgroup analysis (post-hoc, interpret carefully):
Moderate-to-severe pain subgroup (high WOMAC pain): glucosamine + chondroitin combination vs placebo → +20% response rate (79% vs 54%)Mild pain: large placebo effect + no significant supplement effect
GAIT2 (Sawitzke 2010, 2-year continuation):
Clinical outcomes only — this paper measured no structure at allNo arm beat placebo on the primary endpoint (20% WOMAC pain reduction over 24 months): celecoxib 1.21, glucosamine 1.16, combination 0.83, chondroitin alone 0.69, none significantThe investigators went looking for the 2006 moderate-to-severe subgroup signal by testing interaction terms — none was statistically significant. It did not replicateStructure was tested separately (Sawitzke 2008): 24-month joint space width by X-ray, no significant difference. The moderate-to-severe pain subgroup, small magnitude
Other key RCTs + meta-analyses:
MOVES Trial (2016): combination vs celecoxib → non-inferior (but no placebo arm, interpretation caveat)Wandel 2010 BMJ meta-analysis: 10 RCTs, clinical efficacy negative overall (below the minimal clinically important difference)Bruyère 2019 ESCEO guideline: gives prescription-grade crystalline glucosamine sulfate a strong recommendation (GRADE). ESCEO issues only strong/weak — it has no letter grades, so the Level B once quoted here was never in that document2019 OARSI guideline: strongly recommends against every glucosamine and chondroitin formulation — pharmaceutical grade included, not just OTC. This is the strongest negative guideline in the field, and it is the one ESCEO disagrees with2019 ACR / Arthritis Foundation guideline: not recommended (weak evidence)
Why the conclusions are so contested:
GAIT used the HCl salt; some positive RCTs used the sulfate — are they the same?Production / quality variability is large: OTC label content ≠ actual contentSubgroup effects: moderate-to-severe pain may benefit, mild does notPlacebo effect is large: OA pain is subjective; placebo can reach 30-50% improvement
Atlas position:
Overall evidence weak-to-moderateWorth a 3-month trial to see personal response (especially moderate-to-severe pain)Don't expect "new joints"Does not replace weight loss + strength training + physiotherapy + NSAIDs + medical evaluation
追踪两年之后 · 软骨没保住, 微弱的信号还在
GAIT2 · 又追踪了两年同一批研究者把随访延长, 做了 GAIT2。结论没有翻盘: 用 MRI 量的软骨厚度没有被保住——也就是说, 它没有表现出保护结构的能力。中重度疼痛那个亚组里的微弱疼痛信号一直还在, 但幅度很小。
注意这两句话说的是两件不同的事: 一件是软骨有没有少磨掉一点 (结构终点), 一件是你到底疼不疼 (症状终点)。它们为什么能各走各的, 下一页专门拆。
除了 GAIT, 别的证据怎么说
后来还有一批试验和各国指南反复评估过它, 结论大同小异: 放到整个人群看, 疗效弱到基本等于没有。主流的骨关节炎指南大多不把它列为推荐用药, 少数只肯说可以个体化试一试——翻译过来就是不反对你试, 但别抱指望。
这就是这一岛给它的定位: 既不是骗局, 也不是良药, 而是一个信号存在、但很弱的东西。
机制 · 膝盖疼的其实不是软骨
GAIT 里有两个结果放在一起看很奇怪: 软骨厚度没被保住, 可中重度疼痛那群人的疼痛信号却一直微弱地存在。软骨没变好, 疼却可能好一点——这两件事怎么会同时成立?答案是: 疼从来就不是软骨发出来的。
软骨里没有神经, 也没有血管
关节软骨是贴在骨头末端的一层又白又滑的组织, 任务是让两根骨头几乎无摩擦地互相滑动。为了做到这一点, 它必须又光滑又致密——于是它既不长血管, 也不长神经末梢。这意味着: 软骨磨掉一半, 那块软骨本身不会疼, 因为它根本没有报信的线路。
那疼是从哪儿来的? 从软骨周围那几个有神经的地方来的:
滑膜: 关节内侧那层负责分泌滑液的薄膜。磨下来的软骨碎屑掉进关节腔, 会被滑膜里的免疫细胞当成异物去清理, 于是滑膜发炎、充血、肿胀——它上面布满神经末梢, 一肿就疼。这种疼发胀、发热, 休息也不太缓解软骨下骨: 软骨底下那层骨头, 神经密集。软骨变薄之后, 走路时的冲击不再被那层减震垫吸收, 直接砸在骨头上, 久了会出现微骨折和骨髓水肿——这是深部的、一承重就加重的钝痛关节囊和韧带: 关节一肿就被撑开, 那种绷紧感和晨起僵硬感来自这里周围的肌肉: 因为疼而长期绷紧、代偿, 自己也会变成一个新的疼痛来源
所以两件事可以同时成立
一个东西如果能把滑膜那点炎症压下去一些, 你就会觉得没那么疼——而它完全不需要让软骨变厚。反过来, 一个真能保住软骨的东西, 短期内也未必让你今天走路更轻松。疼痛终点和结构终点是两条独立的线: 试验里必须分开量, 你自己评估时也该分开看。
这条机制还顺手解释了前一幕那个反常识的现象: 为什么片子很糟的人可能不痛, 片子轻的人可能痛得厉害——因为片子量的是软骨的厚薄, 而痛不痛取决于滑膜在不在发炎、软骨下骨扛不扛得住, 这两件事和软骨厚度只是松散相关。
它还给了你一个更实际的用法: 评估任何一种关节办法时, 先问它想动的是哪一头——是想让软骨少磨一点 (慢、难、要几年才看得出), 还是想让滑膜别那么发炎 (快、可感、几周就知道)。两者的时间尺度完全不同, 拿三个月去检验前者, 本来就检验不出来。
为什么吵了这么多年还没个定论
一个东西如果真的完全没用, 通常吵不了这么多年。葡萄糖胺之所以吵到今天, 是几件事凑在了一起——每一件都足以让不同的试验得出不同的结果。用的盐不一样: 做出阳性结果的试验多用欧洲那种处方级硫酸盐, GAIT 用的是盐酸盐。两者是不是真等同, 至今没人说得准 (下一页把这笔账算细)。
产品里到底有多少: 药店里便宜产品的实际含量常和标签对不上。一个含量只有标签一半的产品, 做出来当然是阴性结果——但那测的是这个产品, 不是这个分子。
受益的人可能只是一小撮: 亚组里中重度疼痛的人可能受益、轻度的人没反应。把两群人混在一起平均, 一个真实存在的小效应会被稀释到看不见。这也是为什么总体阴性和有些人确实好转能同时是真的。
疼痛本来就极容易被安慰剂影响: 骨关节炎的痛是主观的、有起伏的, 光靠安慰剂就能让三到五成人觉得好转。要在这么大的背景噪音上测出一个小效应, 需要的样本量非常大——而多数试验没那么大。
把这四条合起来, 你会得到一个很实用的判断: 关于这类补剂, 单看某一项试验的结论意义不大, 该看的是把它们汇总之后还剩多少效应。汇总之后剩下的, 就是很弱。
Sulfate vs HCl · prescription Dona reality
"Why are some RCTs positive and others negative?" — much depends on which salt was used.Glucosamine sulfate vs glucosamine hydrochloride:
Chemical difference: counter-ion differs; glucosamine itself is identicalContent: sulfate 1500 mg = 1180 mg glucosamine; HCl 1500 mg = 1240 mg glucosamine (slightly more)Bioavailability: most studies show similar (25-44% absorbed orally, mainly in the small intestine)
Why people perceive "sulfate" as better:
European prescription-grade Dona (Rotta, Italy, originator) is crystalline glucosamine sulfate (CGS) + strict quality controlMost positive RCTs (Reginster 2001 Lancet / Pavelka 2002) used DonaGAIT 2006 NEJM used glucosamine HCl → negativeThe driver may not be "different salt" but "Dona's extreme quality":1500 mg label = 1500 mg actual99%+ purityOnce-daily (single 1500 mg) rather than divided3+ years of sustained research
Bruyère 2019 ESCEO guideline stance:
Patented crystalline glucosamine sulfate (Dona) receives a STRONG recommendation (GRADE) for knee OA. ⚠️ ESCEO issues only strong or weak — there is no letter scale in that document, so the Level B this page used to quote was never in itOTC glucosamine (HCl or sulfate, non-Dona) is not recommendedThis is a clear illustration of the "pharmaceutical-grade vs nutritional-supplement-grade" gap
Practical implications:
European patients: prescription-grade Dona (¥500+/month) costs more than OTC but has stronger RCT supportUS / China: no Dona prescription, third-party certified OTC (Doctor's Best / Now Foods, etc., USP/NSF) is the next-bestAvoid: cheap OTC without third-party certification (label content may be inflated / actual content low / purity low)
Chondroitin sulfate quality varies just as widely:
European prescription-grade: high purity (95%+) + standardised molecular weightOTC: often adulterated with glucan sulfate (from animal-cartilage by-products) — cheap but biologically different⚠️ A figure claiming 55-75% average purity from third-party testing of 20 OTC chondroitins used to sit here. The paper it named cannot be found, so the number is gone. Adulteration is real and documented qualitatively; the repo simply has no verified quantitative source for it yet
OTC quality checklist + practice
Quality buying guide:1. Third-party certification: USP / NSF / ConsumerLab Approved
2. Brands: Doctor's Best, Jarrow, Now Foods, Pure Encapsulations, Thorne — internationally reputable
3. Clear form: "Glucosamine sulfate 1500 mg" rather than "joint complex"
4. Avoid: "Magic joint formula with 20 ingredients" — usually diluted + marketing-driven
5. Price vs content: ¥100-300/month reasonable; ¥30-50/month likely counterfeit; ¥500+/month not necessarily better
Atlas practice:
Want glucosamine + chondroitin → can access Dona (Europe / overseas): use DonaCannot access Dona: use a USP-certified OTC glucosamine sulfate 1500 mg/day + chondroitin 1200 mg/day3-month trial → WOMAC assessment → decide to continue / stopDon't choose uncertified products just because they're cheaper — wasted money can exceed the savings
Chapter 3
Alternatives
Alternatives
OA treatment hierarchy (by evidence + ROI):
Weight loss + exercise (first-line, Level A):
10% weight loss → ↓ knee pain 50% (Messier 2013 IDEA Trial)Strength training + aerobic → cartilage protection + pain improvementFar surpasses any supplementZero side effects
NSAIDs (acute inflammation, Level B-A):
Oral: ibuprofen / naproxen / diclofenac (mind GI + cardiac + renal side effects)Topical: diclofenac gel — minimal systemic side effects, should be a first-line trialCelecoxib: selective COX-2, lower GI risk but slightly higher CV risk
Acetaminophen (Tylenol) (mild):
Weak but safe (except with heavy alcohol / liver disease)Modern guidelines have downgraded it — no longer first-choice, still useful
Intra-articular injections:
Glucocorticoid: short-term (3-6 months) pain relief; repeated injection may accelerate cartilage degenerationHyaluronic acid: mixed evidence, not recommended by some guidelinesPRP (platelet-rich plasma): emerging, evidence still building
Surgery (late-stage):
Meniscal repair / partial / total knee / total hip replacementConsider only when conservative therapy fails
The real role of glucosamine + chondroitin:
Adjunct — not first-lineIn patients with persistent moderate pain after weight loss + training + NSAIDs, worth a 3-month trialTrial design: simultaneously record pain score + function, evaluate objectivelySubstantial improvement at 3 months: personal benefit, continueNo clear improvement at 3 months: stop, save money
Evidence for other popular joint supplements:
MSM (methylsulfonylmethane): Level B-C, some small trials positive, large RCTs missingCurcumin: anti-inflammatory signal; atlas curcumin/mechanism L4 covers bioavailability issuesOmega-3: weak signal, more systemic anti-inflammatory than joint-specificCollagen peptides: see atlas collagen-peptides story, moderate evidence (Clark 2008 RCT)Boswellia: moderate evidence (Boswellia serrata extract)SAMe: some positive studies, but expensive + SSRI interactionsVitamin D: in deficient individuals, supplementation may reduce some joint pain (atlas vitamin-d story)
Debunking "chicken feet / pig trotters / bone broth nourish joints":
These foods contain trace collagen + glucosamineBut are digested into amino acids + monosaccharides — cannot be targeted to jointsA simplified version of "you are what you eat" — atlas collagen-peptides debunks in detailEating these does not directly nourish joints, but the protein + zinc is useful for cartilage (indirectly)
Weight loss + exercise (first-line, Level A):
10% weight loss → ↓ knee pain 50% (Messier 2013 IDEA Trial)Strength training + aerobic → cartilage protection + pain improvementFar surpasses any supplementZero side effects
NSAIDs (acute inflammation, Level B-A):
Oral: ibuprofen / naproxen / diclofenac (mind GI + cardiac + renal side effects)Topical: diclofenac gel — minimal systemic side effects, should be a first-line trialCelecoxib: selective COX-2, lower GI risk but slightly higher CV risk
Acetaminophen (Tylenol) (mild):
Weak but safe (except with heavy alcohol / liver disease)Modern guidelines have downgraded it — no longer first-choice, still useful
Intra-articular injections:
Glucocorticoid: short-term (3-6 months) pain relief; repeated injection may accelerate cartilage degenerationHyaluronic acid: mixed evidence, not recommended by some guidelinesPRP (platelet-rich plasma): emerging, evidence still building
Surgery (late-stage):
Meniscal repair / partial / total knee / total hip replacementConsider only when conservative therapy fails
The real role of glucosamine + chondroitin:
Adjunct — not first-lineIn patients with persistent moderate pain after weight loss + training + NSAIDs, worth a 3-month trialTrial design: simultaneously record pain score + function, evaluate objectivelySubstantial improvement at 3 months: personal benefit, continueNo clear improvement at 3 months: stop, save money
Evidence for other popular joint supplements:
MSM (methylsulfonylmethane): Level B-C, some small trials positive, large RCTs missingCurcumin: anti-inflammatory signal; atlas curcumin/mechanism L4 covers bioavailability issuesOmega-3: weak signal, more systemic anti-inflammatory than joint-specificCollagen peptides: see atlas collagen-peptides story, moderate evidence (Clark 2008 RCT)Boswellia: moderate evidence (Boswellia serrata extract)SAMe: some positive studies, but expensive + SSRI interactionsVitamin D: in deficient individuals, supplementation may reduce some joint pain (atlas vitamin-d story)
Debunking "chicken feet / pig trotters / bone broth nourish joints":
These foods contain trace collagen + glucosamineBut are digested into amino acids + monosaccharides — cannot be targeted to jointsA simplified version of "you are what you eat" — atlas collagen-peptides debunks in detailEating these does not directly nourish joints, but the protein + zinc is useful for cartilage (indirectly)
临床 · 止痛的几个台阶, 以及各自的代价
减重加运动是地基, 但地基起效慢, 而痛是现在就痛。下面这几个台阶按效果加代价从轻到重排。消炎药 (NSAID)
疼得急、关节有炎症的时候, 消炎药是真的有效——它按住的正是让滑膜持续发炎、让痛觉神经越来越敏感的那条通路。代价在于:
口服 (布洛芬、萘普生这类): 有效, 但伤胃、伤心、伤肾, 长期吃尤其要当心涂在膝盖上的双氯芬酸凝胶: 药主要停在局部, 全身副作用很小, 值得优先试; 膝盖这种位置浅的关节尤其适合塞来昔布 (Celecoxib): 对胃肠更友好, 但心血管风险略高对乙酰氨基酚 (Tylenol, 即扑热息痛): 更弱但更安全; 现在的指南已经把它从首选的位置降了下来, 不过仍然有用
往关节腔里打针
类固醇: 直接把滑膜的炎症按下去, 短期 (3-6 个月) 止痛效果好。但反复打反而可能加速软骨退化, 所以它是一座桥, 不是长期方案透明质酸: 想补的是滑液的润滑性, 证据很混PRP (富血小板血浆): 抽自己的血浓缩血小板再打回关节, 商业上很火, 证据同样很混, 部分指南不推荐
(这三样的细节、费用和指南分歧, 在决策树那一幕的深度页里有完整版。)
手术
到了晚期、所有保守办法都无效, 才轮到手术——从半月板修复到全膝、全髋置换。手术能换掉磨坏的关节面, 但换不回肌肉和习惯, 术后恢复靠的还是力量训练。
把这几个台阶放回顺序里: 越靠前的越便宜、越安全, 也越需要你自己花时间; 越靠后的越快、越贵、越不可逆。葡萄糖胺加软骨素坐在基础做完了、还差一点的那一格, 不在任何一个台阶的前面。
其它关节补剂 · 证据强弱一览
关节这块的补剂货架很挤, 顺手把常听到的几个按证据排一排 (这里只说证据强弱, 机制细节各自在对应的岛上):MSM (甲基硫黄): 只有零星小试验支持, 缺大试验姜黄素: 有抗炎信号, 但它天生吸收极差, 这个问题在 curcumin 那一岛细讲omega-3: 偏全身抗炎, 不是专门冲着关节去的胶原肽: 关节方向的证据其实比葡萄糖胺还硬一点, 见 collagen-peptides 那一岛乳香 (Boswellia): 证据中等SAMe: 有点用, 但贵, 而且和抗抑郁药 SSRI 打架维生素 D: 本来就缺的人补上之后, 关节痛也可能缓一些; 不缺的人补了没有额外好处
看这张表有个通用的读法: 这些东西的效应量普遍都不大, 而它们要挑战的对手 (减重、力量训练) 效应量很大。所以真正的问题从来不是这个补剂有没有一点点用, 而是在你有限的时间和钱里, 它排第几。
误区 · 吃软骨就能补软骨吗
鸡爪、猪蹄、骨头汤能补关节——这是华语世界里最粘人的一条说法。它确实有一点道理的影子: 这些东西里真的含有胶原和一点葡萄糖胺。但道理在进了胃之后就断了。为什么断在胃里
蛋白质和多糖都是大分子, 肠壁不会整块放行。胃酸先把胶原的三股螺旋拆散, 胰腺和肠壁的蛋白酶再把它剪成一个个氨基酸和短肽; 糖链那边同样被剪成单糖。真正进入血液的, 是氨基酸、短肽和单糖这些通用零件——它们身上没有任何标签写着我来自软骨, 请送去膝盖。
进了血, 这些零件汇进全身的氨基酸池和糖池, 哪里在造东西就往哪里去: 可能被拿去修肌肉、可能被拿去造酶、也可能直接烧掉供能。分给关节软骨的那一份, 由软骨细胞当时在不在合成基质决定, 和你早上喝的是骨头汤还是豆浆关系不大。
这就是吃什么补什么的简化版。同一个逻辑在站内反复出现: 吃猪脑不补脑, 吃胶原不直接长成皮肤里的胶原, 吃软骨也不直接长成软骨。身体拆解再重建的这道工序, 把原料的出身这个信息彻底抹掉了。
再叠上前面那一关: 软骨没有血管。就算血里真的多了一点原料, 也没有一条管道直通软骨细胞, 还得靠关节活动一点一点渗进去。
那这些汤菜是不是白吃了?
也不是。里面的蛋白质、锌这些确实是软骨基质合成要用的原料, 只是它们是通用原料——你吃鸡蛋、瘦肉、豆制品同样拿得到, 而且更便宜、脂肪更少。所以喝骨头汤没错, 错的是把它当成一种定向补关节的手段。
Chapter 4
Decision tree
Decision tree
"My knees hurt — should I try glucosamine?" — pathway:
Step 1 · Evaluation:
See a doctor first (orthopaedics / rheumatology): rule out secondary OA + rheumatoid + gout + meniscal tearImaging (X-ray / MRI) to assess degenerationMeasure weight + BMI + waist
Step 2 · First-line intervention (priority):
5-10% weight loss (if overweight)Strength training: quadriceps + hip + core (reduces knee load)Low-impact aerobic: swimming + cycling + elliptical (avoid high impact such as running until pain reduces)PhysiotherapyTopical NSAID gel (during acute flares)
Step 3 · Add glucosamine + chondroitin?
YES (reasonable trial):
Moderate-to-severe pain after 6-12 weeks of first-lineDon't want oral NSAIDs (GI / CV / renal concerns)Affordable ($20-50/month)Willing to trial 3 months and assess objectively
nitric oxide: A small signal molecule from the vessel lining that relaxes the vessel-wall muscle so the vessel widens. (not recommended):
Mild pain (placebo effect large)Limited budget (not the highest-ROI intervention)First-line interventions not yet done (build the base first)
Step 4 · Form + dose:
Glucosamine sulfate 1500 mg/day (European prescription dose), ORGlucosamine sulfate 500 mg × 3/day+ chondroitin sulfate 1200 mg/day (optional, GAIT combination)Quality brands: look for USP / NSF third-party certification + label accuracy
Step 5 · 3-month evaluation:
WOMAC pain / function questionnaire (available online)Compare baseline vs 3 monthsSubstantial improvement (≥ 30%): personal benefit, continueMild improvement (10-20%): possibly placebo, depends on willingness to payNo improvement: stop, save money
Safety:
Very safe (except shellfish allergy — glucosamine comes from shrimp/crab)Diabetes: large doses may slightly raise fasting glucose (1-3%), monitorWarfarin: may raise INR, monitorPregnancy / breastfeeding: lacks data, skip
Cost-effectiveness:
OTC glucosamine + chondroitin: ¥100-300/month (mainstream brands)European prescription glucosamine sulfate (Dona): ¥500+/month (but more solid evidence)vs a pair of good running shoes / a year of gym / one surgery: ROI varies
Important warnings:
Don't endure joint pain: long-untreated → gait change → hip / back / contralateral knee compensatory injury"A pill cannot rebuild cartilage": most radiographic cartilage loss is irreversibleEarly intervention (weight loss + training) prevents progression → more effective than any late-stage supplement
Connections to other atlas stories:
collagen-peptides (stronger joint RCT evidence than glucosamine)curcumin (anti-inflammatory)bone + muscle L3vitamin-d + calcium + vitamin-k2 (bone health)omega-3 (systemic anti-inflammatory)
Atlas position: glucosamine + chondroitin is the supplement world's exemplar of "signal exists, but isn't strong" — the atlas must honestly report the overall null RCTs while acknowledging that some patients benefit. No fear-selling, no perfection-selling. Your money, your call.
Step 1 · Evaluation:
See a doctor first (orthopaedics / rheumatology): rule out secondary OA + rheumatoid + gout + meniscal tearImaging (X-ray / MRI) to assess degenerationMeasure weight + BMI + waist
Step 2 · First-line intervention (priority):
5-10% weight loss (if overweight)Strength training: quadriceps + hip + core (reduces knee load)Low-impact aerobic: swimming + cycling + elliptical (avoid high impact such as running until pain reduces)PhysiotherapyTopical NSAID gel (during acute flares)
Step 3 · Add glucosamine + chondroitin?
YES (reasonable trial):
Moderate-to-severe pain after 6-12 weeks of first-lineDon't want oral NSAIDs (GI / CV / renal concerns)Affordable ($20-50/month)Willing to trial 3 months and assess objectively
nitric oxide: A small signal molecule from the vessel lining that relaxes the vessel-wall muscle so the vessel widens. (not recommended):
Mild pain (placebo effect large)Limited budget (not the highest-ROI intervention)First-line interventions not yet done (build the base first)
Step 4 · Form + dose:
Glucosamine sulfate 1500 mg/day (European prescription dose), ORGlucosamine sulfate 500 mg × 3/day+ chondroitin sulfate 1200 mg/day (optional, GAIT combination)Quality brands: look for USP / NSF third-party certification + label accuracy
Step 5 · 3-month evaluation:
WOMAC pain / function questionnaire (available online)Compare baseline vs 3 monthsSubstantial improvement (≥ 30%): personal benefit, continueMild improvement (10-20%): possibly placebo, depends on willingness to payNo improvement: stop, save money
Safety:
Very safe (except shellfish allergy — glucosamine comes from shrimp/crab)Diabetes: large doses may slightly raise fasting glucose (1-3%), monitorWarfarin: may raise INR, monitorPregnancy / breastfeeding: lacks data, skip
Cost-effectiveness:
OTC glucosamine + chondroitin: ¥100-300/month (mainstream brands)European prescription glucosamine sulfate (Dona): ¥500+/month (but more solid evidence)vs a pair of good running shoes / a year of gym / one surgery: ROI varies
Important warnings:
Don't endure joint pain: long-untreated → gait change → hip / back / contralateral knee compensatory injury"A pill cannot rebuild cartilage": most radiographic cartilage loss is irreversibleEarly intervention (weight loss + training) prevents progression → more effective than any late-stage supplement
Connections to other atlas stories:
collagen-peptides (stronger joint RCT evidence than glucosamine)curcumin (anti-inflammatory)bone + muscle L3vitamin-d + calcium + vitamin-k2 (bone health)omega-3 (systemic anti-inflammatory)
Atlas position: glucosamine + chondroitin is the supplement world's exemplar of "signal exists, but isn't strong" — the atlas must honestly report the overall null RCTs while acknowledging that some patients benefit. No fear-selling, no perfection-selling. Your money, your call.
试用方案 · 谁值得试、吃多少、三个月后怎么算账
谁值得试基础做了 6-12 周, 还剩中到重度疼痛不想吃口服消炎药 (怕伤胃伤肾)每月花个几十到上百块能接受并且愿意认真试三个月再下判断
谁别试
只是轻微痛: 安慰剂效应太大, 你很容易骗自己预算紧张: 它性价比不高, 同样的钱去买双合脚的鞋、报个训练课, 回报都更大基础都还没做: 先把减重和力量训练做起来, 那才是效应量最大的一格
剂型和量
葡萄糖胺硫酸盐每天 1500 mg (欧洲处方剂量), 或者拆成 500 mg 一天三次想加软骨素就每天 1200 mg (GAIT 用的联合方案)认准带 USP 或 NSF 第三方认证的牌子, 别买标签含量都靠不住的廉价货
三个月后怎么算账
找一份 WOMAC 疼痛和功能问卷 (网上有), 把开始时和三个月后的分数放在一起比:
明显好转 (30% 以上): 它对你有用, 继续只好一点点 (10-20%): 多半是安慰剂在起作用, 看你愿不愿意继续付这笔钱完全没变: 停, 省钱
为什么一定要把分数写下来再比? 因为疼痛本来就有起伏, 而人对我最近好像好点了这件事的记忆极不可靠——今天恰好不疼, 你就会把它记成药起效了。写下来的分数不会替你圆场。
还有一条时间上的提醒: 三个月这个窗口检验的是疼痛那一头, 不是软骨那一头。软骨的变化以年计, 任何三个月的试用都看不到它——所以没变好这个结论, 说的只是你的疼痛没变好。
安全性 · 这几种人要避开或盯紧
整体上它很温和——毕竟它本来就是身体里天天在造的东西, 大剂量口服的主要问题并不是毒性。但有几处要留神:甲壳类过敏: 葡萄糖胺多是从虾蟹壳里提取的, 对甲壳过敏的人别用糖尿病: 它本身是一种氨基糖, 大剂量时可能让空腹血糖略升 (1-3%)。幅度不大, 但正在调药的人要监测正在吃华法林 (Warfarin) 的人: 凝血可能被它影响, 要盯着 INR。这一条最要紧, 因为万一出事是出血, 不是不舒服孕期和哺乳期: 没有数据, 直接跳过
把前面那两句提醒展开
关节痛别硬忍。 痛的时候人会不自觉地改变走路姿势去躲开那个痛点: 患侧少受力、步子变短、骨盆歪一点。这套代偿会把负荷转嫁给髋、腰和另一条腿的膝盖, 它们再各自代偿下去——于是最后要处理的关节从一个变成三个, 而后来那两个本来是好的。
药丸补不回已经磨掉的软骨。 影像上的软骨损失大多不可逆: 软骨里没有血管, 修复所需的细胞和原料进不去, 而软骨细胞本身分裂能力极弱, 成年之后基本不再重建那层基质。所以真正的杠杆一直在前面——早点减重加训练去防退化, 永远比晚期靠任何补剂管用。
Joint injections · steroid / HA / PRP / stem
"Glucosamine isn't working / enough — what's next?" — joint-injection + surgery decision tree.Intra-articular injections:
Glucocorticoid:
Methylprednisolone / triamcinolone / betamethasoneEffect: marked pain relief for 3-6 weeks (70-80% of patients)Downsides:Repeated injection (> 4/year same joint) accelerates cartilage degeneration (McAlindon 2017 JAMA)Transient blood-sugar rise (DM patients)Intra-articular infection risk ~ 1/3000, rare but seriousClinical role: short bridge for acute flare or mid-to-late OA
Hyaluronic acid (HA):
A constituent of joint synovial fluid; increases lubrication3-5 weekly injections, relief lasting 4-6 monthsGuideline disagreement:AAOS 2021: not recommended for routine use (Moderate strength)OARSI 2019: conditional recommendationThe Cochrane viscosupplementation review stops at Bellamy 2006 and has never been updated since — the Cochrane 2015 this page used to cite does not existSynvisc / Hyalgan etc.Cost ¥3000-8000/sessionIndividual decision: some patients benefit subjectively, some do not
PRP (Platelet-Rich Plasma):
Autologous platelet-rich plasma injection into the jointContains growth factors (PDGF / TGF-β / IGF-1 / VEGF) → promotes repair theoreticallyEvidence:Bennell 2021 JAMA (RESTORE trial, N = 288 knee OA): PRP vs placebo at 12 months → no significant pain differenceEarly small trials positive → large RCT negative (similar to the GAIT story)The two bodies disagree: OARSI 2019 strongly recommends against, while AAOS 2021 gives a Limited-strength recommendation that it may reduce pain and improve function — neither for nor against. Guidelines disagreeing is itself the signal that the evidence is thinCommercially popular, heavily marketed in private clinics, ¥3000-8000/sessionAtlas position: weak evidence + high cost, not recommended
Stem cells / mesenchymal (MSC):
Plenty of hype, very weak clinical evidenceSome Chinese hospitals / overseas stem-cell centres charge ¥50,000-150,000FDA warning: most unapproved "stem-cell therapies" are ineffective + riskyNot recommended
mcalindon-2017-jama-corticosteroidbennell-2021-jama-restore-prpclark-2008-collagen-joint
Surgery decision + timing + save vs replace
Surgery — when to consider:Conservative treatment (all of the above ineffective for 12+ months) + late-stage imaging (Kellgren-Lawrence 3-4) + severely impacted quality of life:
Arthroscopic debridement: Moseley 2002 NEJM showed no difference vs sham surgery, not recommendedPartial meniscectomy: indicated only for acute tear + mechanical locking symptomsOsteotomy: single-compartment OA + young + active patients, realigns mechanical axisUnicompartmental knee arthroplasty (UKA): single-compartment late stage, preserves ligaments, fast recoveryTotal knee arthroplasty (TKA):Gold standard; 95% of patients improve substantially within 10 yearsSuited to 60+ y/o + severe OA + failed conservative therapyProsthesis lifespan 15-20 yearsRisks: infection 1-2% / VTE 1-3% / loosening / revision
Timing of surgery:
Too early: prosthesis lifespan 15-20 years → done at 50 may need revision at 70, secondary surgery success rate is lowerToo late: chronic pain → gait + cardiovascular + depression worsensIdeal: 65+ y/o + late-stage imaging + failed conservative therapy + serious quality-of-life impact
The real "save the joint vs replace the joint" balance:
45-60 y/o moderate OA: weight loss + training + physiotherapy + occasional NSAID + steroid bridge — delay and maintain60-70 y/o late OA: evaluate surgery (UKA / TKA)70+ y/o active: surgical-risk vs benefit assessment
Atlas connections: bone + muscle + sarcopenia (post-op recovery requires strength); cardiovascular (surgical risk); endocrine/metabolic-syndrome (weight loss is the prerequisite to everything).
References · 9
- Clegg, D. O., Reda, D. J., Harris, C. L., Klein, M. A., O'Dell, J. R., Hooper, M. M., et al. (2006). Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine, 354(8), 795-808. 10.1056/NEJMoa052771
- Wandel, S., Jüni, P., Tendal, B., Nüesch, E., Villiger, P. M., Welton, N. J., Reichenbach, S., & Trelle, S. (2010). Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ, 341, c4675. 10.1136/bmj.c4675
- Sawitzke, A. D., Shi, H., Finco, M. F., Dunlop, D. D., Harris, C. L., Singer, N. G., et al. (2010). Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT. Annals of the Rheumatic Diseases, 69(8), 1459-1464. GAIT 2-year continuation, CLINICAL outcomes only — no imaging, no cartilage. No arm beat placebo on 20% WOMAC pain reduction, and the interaction terms for the moderate-severe pain subgroup were NOT significant: the 2006 subgroup signal did not replicate. 10.1136/ard.2009.120469
- Sawitzke, A. D., Shi, H., Finco, M. F., Dunlop, D. D., Bingham, C. O., Harris, C. L., et al. (2008). The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: A report from the glucosamine/chondroitin arthritis intervention trial. Arthritis & Rheumatism, 58(10), 3183-3191. This is the GAIT structural arm: 24-month joint space width by X-RAY, no significant difference between groups. The story used to attribute "MRI cartilage thickness" to the 2010 clinical paper. 10.1002/art.23973
- Bruyère, O., Honvo, G., Veronese, N., Arden, N. K., Branco, J., Curtis, E. M., et al. (2019). An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Seminars in Arthritis and Rheumatism, 49(3), 337-350. ESCEO uses GRADE strong/weak, not letter grades. It gives prescription-grade crystalline glucosamine sulfate a STRONG recommendation — "Level B" was never in this document. 10.1016/j.semarthrit.2019.04.008
- Bannuru, R. R., Osani, M. C., Vaysbrot, E. E., Arden, N. K., Bennell, K., Bierma-Zeinstra, S. M. A., Kraus, V. B., Lohmander, L. S., Abbott, J. H., Bhandari, M., Blanco, F. J., Espinosa, R., Haugen, I. K., Lin, J., Mandl, L. A., Moilanen, E., Nakamura, N., Snyder-Mackler, L., Trojian, T., … McAlindon, T. E. (2019). OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis and Cartilage, 27(11), 1578–1589. 10.1016/j.joca.2019.06.011
- Messier, S. P., Mihalko, S. L., Legault, C., Miller, G. D., Nicklas, B. J., DeVita, P., et al. (2013). Effects of intensive diet and exercise on knee joint loads, inflammation, and clinical outcomes among overweight and obese adults with knee osteoarthritis (IDEA). JAMA, 310(12), 1263-1273. 10.1001/jama.2013.277669
- Brophy, R. H., & Fillingham, Y. A. (2022). AAOS clinical practice guideline summary: management of osteoarthritis of the knee (nonarthroplasty), third edition. Journal of the American Academy of Orthopaedic Surgeons, 30(9), e721-e729. On PRP it gives a LIMITED-strength recommendation IN FAVOUR ('may reduce pain and improve function'), which is not the same as recommending against — OARSI is the body that recommends against. 10.5435/JAAOS-D-21-01233
- Bellamy, N., Campbell, J., Welch, V., Gee, T. L., Bourne, R., & Wells, G. A. (2006). Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database of Systematic Reviews, (2), CD005321. 10.1002/14651858.CD005321.pub2